logo
ResearchBunny Logo
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

Medicine and Health

A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

P. R. Shiroma, P. Thuras, et al.

This groundbreaking study by Paulo R. Shiroma and colleagues investigates the efficacy and safety of repeated versus single subanesthetic ketamine infusions for treatment-resistant depression. While no significant difference was observed in primary outcomes, the results hint at potential benefits of repeated ketamine infusions, paving the way for further research to optimize treatment.

00:00
00:00
~3 min • Beginner • English
Abstract
The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine. However, consensus guideline stated the lack of evidence to support frequent ketamine administration. We compared the efficacy and safety of single vs. six repeated ketamine using midazolam as active placebo. Subjects received either six ketamine or five midazolam followed by a single ketamine during 12 days followed by up to 6-month post-treatment period. The primary end point was the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 h after the last infusion. Fifty-four subjects completed all six infusions. For the primary outcome measure, there was no significant difference in change of MADRS scores between six ketamine group and single ketamine group at 24 h post-last infusion; however, remission and response favored the six ketamine after infusion 4 and 5, respectively, compared to midazolam before receiving single ketamine infusion. Remission and response favored the six ketamine after infusion 4 and 5, respectively, compared to midazolam before receiving single ketamine infusion. For those who responded, the median time-to-relapse was nominally but not statistically different (2 and 6 weeks for the single and six ketamine groups, respectively). Repeated infusions were relatively well-tolerated. Repeated ketamine showed better antidepressant efficacy to midazolam after five infusions but fell short of significance when compared to add-on single ketamine to midazolam at the end of 2 weeks. Increasing knowledge on the mechanism of ketamine should drive future studies on the optimal dosing of ketamine for maximum antidepressant efficacy with minimum exposure.
Publisher
Translational Psychiatry
Published On
Nov 16, 2020
Authors
Paulo R. Shiroma, Paul Thuras, Joseph Wels, C. Sophia Abbott, Christopher Erbes, Susannah Tye, Kelvin O. Lim
Tags
ketamine
depression
treatment-resistant depression
subanesthetic infusions
efficacy
placebo-controlled
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny